Core Scientific, Inc. (NASDAQ:CORZ – Get Free Report) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 44,670,000 shares, a growth of 13.2% from the December 31st total of 39,460,000 shares. Based on an average daily trading volume, of 10,740,000 shares, the short-interest ratio is currently 4.2 days. Currently, 18.5% of the company’s shares are sold short.
Analysts Set New Price Targets
Several equities research analysts have commented on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $17.00 price target on shares of Core Scientific in a research report on Thursday, November 7th. Jefferies Financial Group assumed coverage on shares of Core Scientific in a research report on Monday, October 28th. They set a “buy” rating and a $19.00 price target on the stock. Craig Hallum assumed coverage on shares of Core Scientific in a research report on Tuesday, January 21st. They set a “buy” rating and a $24.00 price target on the stock. BTIG Research boosted their price target on shares of Core Scientific from $19.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Finally, Macquarie boosted their price target on shares of Core Scientific from $16.00 to $19.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. Fifteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $19.07.
Get Our Latest Analysis on Core Scientific
Insider Activity
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of CORZ. Newbridge Financial Services Group Inc. acquired a new position in shares of Core Scientific during the 4th quarter worth approximately $42,000. Sunbelt Securities Inc. acquired a new position in shares of Core Scientific during the 2nd quarter worth approximately $33,000. Rise Advisors LLC grew its position in shares of Core Scientific by 14.3% during the 3rd quarter. Rise Advisors LLC now owns 8,000 shares of the company’s stock worth $95,000 after purchasing an additional 1,000 shares in the last quarter. KBC Group NV acquired a new position in shares of Core Scientific during the 4th quarter worth approximately $114,000. Finally, Villere ST Denis J & Co. LLC acquired a new position in shares of Core Scientific during the 4th quarter worth approximately $140,000.
Core Scientific Price Performance
Core Scientific stock traded down $0.36 during trading hours on Monday, hitting $11.91. The company had a trading volume of 5,390,002 shares, compared to its average volume of 12,620,471. The firm has a market cap of $3.33 billion and a PE ratio of -2.20. Core Scientific has a one year low of $2.61 and a one year high of $18.63. The firm has a 50-day moving average of $15.03 and a 200 day moving average of $13.04.
Core Scientific (NASDAQ:CORZ – Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The business had revenue of $95.35 million for the quarter, compared to analysts’ expectations of $94.80 million. As a group, research analysts expect that Core Scientific will post 0.5 earnings per share for the current year.
About Core Scientific
Core Scientific, Inc provides digital asset mining services in North America. It operates through two segments, Mining and Hosting. The company offers blockchain infrastructure, software solutions, and services; and operates data center mining facilities. It also mines digital assets for its own account; and provides hosting services for other large bitcoin miners, which include deployment, monitoring, trouble shooting, optimization, and maintenance of its customers' digital asset mining equipment.
Featured Stories
- Five stocks we like better than Core Scientific
- How to Find Undervalued Stocks
- Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Big Dividend Hikes: 4 Large-Cap Stocks Increasing Payouts
- What Investors Need to Know to Beat the Market
- Procter & Gamble: A Consumer Staples Titan Built to Win
Receive News & Ratings for Core Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Scientific and related companies with MarketBeat.com's FREE daily email newsletter.